Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article (39)

Advertisement

Research Article Free access | 10.1172/JCI107383

Response of Plasma Histaminase Activity to Small Doses of Heparin in Normal Subjects and Patients with Hyperlipoproteinemia

Stephen B. Baylin, Michael A. Beaven, Ronald M. Krauss, and Harry R. Keiser

Experimental Therapeutics Branch, National Heart and Lung Institute, National Institutes of Health, Bethesda, Maryland 20014

Molecular Disease Branch, National Heart and Lung Institute, National Institutes of Health, Bethesda, Maryland 20014

Find articles by Baylin, S. in: PubMed | Google Scholar

Experimental Therapeutics Branch, National Heart and Lung Institute, National Institutes of Health, Bethesda, Maryland 20014

Molecular Disease Branch, National Heart and Lung Institute, National Institutes of Health, Bethesda, Maryland 20014

Find articles by Beaven, M. in: PubMed | Google Scholar

Experimental Therapeutics Branch, National Heart and Lung Institute, National Institutes of Health, Bethesda, Maryland 20014

Molecular Disease Branch, National Heart and Lung Institute, National Institutes of Health, Bethesda, Maryland 20014

Find articles by Krauss, R. in: PubMed | Google Scholar

Experimental Therapeutics Branch, National Heart and Lung Institute, National Institutes of Health, Bethesda, Maryland 20014

Molecular Disease Branch, National Heart and Lung Institute, National Institutes of Health, Bethesda, Maryland 20014

Find articles by Keiser, H. in: PubMed | Google Scholar

Published August 1, 1973 - More info

Published in Volume 52, Issue 8 on August 1, 1973
J Clin Invest. 1973;52(8):1985–1993. https://doi.org/10.1172/JCI107383.
© 1973 The American Society for Clinical Investigation
Published August 1, 1973 - Version history
View PDF
Abstract

The release of histaminase activity in plasma after small intravenous of heparin was studied in 85 normal subjects and patients. In normal subjects, plasma histaminase activity (basal level, 1.7±0.1 U/ml, mean ±SEM) increased 1.6±0.2 U/ml after 10 U of heparin/kg, 8.5±2.4 U/ml after 20 U/kg, and 33±4.9 U/ml after 75 U/kg. The extent of the increase varied widely among individuals but in a particular individual the response was constant and dose-dependent. Histaminase activity rose to peak levels within 7-15 min and then declined exponentially with a half-life of 40-120 min. This pattern of response was also observed in two patients with the histaminase-producing tumor, medullary carcinoma of the thyroid. A significantly reduced response was observed, however, in 14 patients with type I hyperlipoproteinemia, a disorder in which high plasma triglyceride levels are associated with low postheparin plasma lipolytic activity. After 10 U heparin/kg, plasma histamine activity increased 0.5±0.2 U/ml, and after 75 U heparin/kg, 10.9±5.6 U/ml. In contrast, in 27 patients with other types of hyperlipoproteinemia in whom postheparin lipolytic activity was normal, the increase (2.4±0.6 U/ml) in plasma histaminase activity after 10 U heparin/kg was not significantly different from that of normal subjects. The reduced response of the plasma histaminase activity to heparin in patients with type I hyperlipoproteinemia did not appear to be due to the presence of lipemia or to an inhibitor of the enzyme in plasma. These findings suggest that many patients with type I hyperlipoproteinemia may have deficient release of both lipolytic and histaminase activities into plasma after heparin administration.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1985
page 1985
icon of scanned page 1986
page 1986
icon of scanned page 1987
page 1987
icon of scanned page 1988
page 1988
icon of scanned page 1989
page 1989
icon of scanned page 1990
page 1990
icon of scanned page 1991
page 1991
icon of scanned page 1992
page 1992
icon of scanned page 1993
page 1993
Version history
  • Version 1 (August 1, 1973): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article (39)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts